Dose Finding Study to Evaluate the Safety of BSB-2002 in Relapsed or Refractory Acute Myeloid Leukemia (AML) Patients With NPM1 Mutation
Part of paid clinical trials in St Louis, Missouri.
- Sponsor
- BlueSphere Bio, Inc
- Study ID
- NCT07566585
- Phase
- PHASE1
- Status
- Recruiting
Conditions
- AML - Acute Myeloid Leukemia
- AML With Mutated NPM1
- AML, Adult Recurrent
Eligibility Criteria
- Sex
- ALL
- Age
- 18 Years - N/A
- Healthy Volunteers
- Not accepted
Interventions
- SOC+ BSB-2002 — DRUGPatients will receive BSB-2002 as a single IV infusion at day 1 following the lymphodepletion regime.
- SOC+BSB-2002 — DRUGPatients will receive BSB-2002 as a single IV infusion at day 1 following the lymphodepletion regime.
Study Details
The goal of this clinical trial is to test BSB-2002 which is a new type of cellular therapy to treat blood cancer (AML). It will evaluate the safety of BSB-2002 and also determine whether it works to prevent relapse of your cancer.
Key Dates
- Start date
- Apr 21, 2026
- Status verified
- Apr 2026
- Primary completion
- Aug 31, 2027
- Completion
- Sep 30, 2027
Study Design
- Enrollment
- 19 participants (estimated)
- Allocation
- NON_RANDOMIZED
- Intervention model
- SEQUENTIAL
- Primary purpose
- TREATMENT
Arms
- Experimental: Dose Escalation CohortsAML HLA-A\*02:01 and Positive for NPM1 mutation type A, D, G or H patients with an identified will be dosed in dose escalation cohorts
- Experimental: Expansion CohortOnce the maximum tolerated dose (MTD) or promising dose is reached additional AML HLA-A\*02:01 and Positive for NPM1 mutation type A, D, G or H patients will be enrolled in the expansion cohort.
Primary Outcome Measure
Number of participants with dose-limiting toxicity, adverse events (AEs) and serious AEs (SAEs) [ Time Frame: 365 days ]
Central Contacts
- Medical Director: Nawazish Khan, BlueSphere Bio, MD252-347-4938
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Washington University at St Louis | St Louis | Missouri | 63110 | - |
Find similar trials in St Louis, MO
By research site
Related Studies
- Safety and Tolerability of Ziftomenib Combinations in Patients With Relapsed/Refractory Acute Myeloid LeukemiaPHASE1 · Recruiting · Kura Oncology, Inc. · Gilbert, Arizona
- BSB-1001 in Patients Undergoing HLA-Matched Allogenic Hematopoietic Stem Cell Transplant for AML, ALL or MDSPHASE1/PHASE2 · Recruiting · BlueSphere Bio, Inc · Duarte, California
- A Study of CBX-250 in Participants With Relapsed or Refractory Myeloid LeukemiasPHASE1 · Recruiting · Crossbow Therapeutics, Inc. · Duarte, California
- A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AMLPHASE1 · Recruiting · Kura Oncology, Inc. · Phoenix, Arizona